Drug Trial Radar · NCT06533553
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 9, 2024
Primary completion
Oct 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Areteia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Dexpramipexole DihydrochlorideDrug
Administration of dexpramipexole tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean change in the blood AEC from baseline to Week 16Time frame: Baseline, Week 16
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Research Site US-10001-017
Conway, Arkansas
Research Site US-10001-008
Newport Beach, California
Research Site US-10001-022
Northridge, California
Research Site US-10001-016
Westminster, California
Research Site US-10001-030
Orlando, Florida
Research Site 10001-032
Champaign, Illinois
Research Site US-10001-021
Hammond, Indiana
Research Site US-10001-033
Des Moines, Iowa
Research Site US-10001-020
Baltimore, Maryland
Research Site US-10001-024
Farmington Hills, Michigan
Research Site US-10001-005
Saint Charles, Missouri
Research Site US-10001-001
St Louis, Missouri
Research US-10001-010
Charlotte, North Carolina
Research Site US-10001-025
Charlotte, North Carolina
Research Site US-10001-007
Gastonia, North Carolina
Research Site US-10001-004
Columbus, Ohio
Research Site US-10001-002
DuBois, Pennsylvania
Research Site US-10001-013
Philadelphia, Pennsylvania
Research Site US-10001-023
East Providence, Rhode Island
Research Site US-10001-012
Rock Hill, South Carolina
Research Site US-10001-009
Corsicana, Texas
Research Site US-10001-038
Houston, Texas
Research Site 10001-026
McKinney, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.